Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Relay passes on the lirafugratinib baton
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
November's CHMP meeting sets up a GSK-Novartis battle
Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer.
